457 related articles for article (PubMed ID: 18398153)
21. Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
Charoentum C; Thongprasert S; Chewasakulyong B
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1603-7. PubMed ID: 17940374
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC).
Giorgio CG; Pappalardo A; Russo A; Giuffrida D; Santini D; Petralia G; Castorina S; Nunzio R; Failla G; Bordonaro R
Lung Cancer; 2006 Mar; 51(3):357-62. PubMed ID: 16406602
[TBL] [Abstract][Full Text] [Related]
24. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
[TBL] [Abstract][Full Text] [Related]
25. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).
Lilenbaum RC; Herndon JE; List MA; Desch C; Watson DM; Miller AA; Graziano SL; Perry MC; Saville W; Chahinian P; Weeks JC; Holland JC; Green MR
J Clin Oncol; 2005 Jan; 23(1):190-6. PubMed ID: 15625373
[TBL] [Abstract][Full Text] [Related]
26. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Wakelee HA; Takimoto CH; Lopez-Anaya A; Chu Q; Middleton G; Dunlop D; Ramlau R; Leighl N; Rowinsky EK; Hao D; Zatloukal P; Jacobs CD; Rodon J
Cancer Chemother Pharmacol; 2012 Feb; 69(2):563-71. PubMed ID: 22057855
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
[TBL] [Abstract][Full Text] [Related]
29. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation.
Belani CP; Barstis J; Perry MC; La Rocca RV; Nattam SR; Rinaldi D; Clark R; Mills GM
J Clin Oncol; 2003 Aug; 21(15):2933-9. PubMed ID: 12885812
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer.
Douillard JY; Peschel C; Shepherd F; Paz-Ares L; Arnold A; Davis M; Tonato M; Smylie M; Tu D; Voi M; Humphrey J; Ottaway J; Young K; Vreckem AV; Seymour L
Lung Cancer; 2004 Dec; 46(3):361-8. PubMed ID: 15541822
[TBL] [Abstract][Full Text] [Related]
31. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.
Belani CP; Wang W; Johnson DH; Wagner H; Schiller J; Veeder M; Mehta M;
J Clin Oncol; 2005 Jun; 23(16):3760-7. PubMed ID: 15837967
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of carboplatin and paclitaxel in non-small cell lung cancer patients previously treated with chemotherapy.
Yoh K; Kubota K; Kakinuma R; Ohmatsu H; Goto K; Niho S; Saijo N; Nishiwaki Y
Lung Cancer; 2007 Oct; 58(1):73-9. PubMed ID: 17548127
[TBL] [Abstract][Full Text] [Related]
33. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.
Tell R; Sederholm C; Klintenberg C; Franksson L; Brandén E; Hillerdal G; Lönn U; Lindén CJ; Ewers SB; Lamberg K; Mrazek E; Lödén B; Sjögren A; Linné T; Friesland S; Sirzén F
Anticancer Res; 2008; 28(5B):2851-7. PubMed ID: 19031924
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
Nakadate M; Yamazaki K; Konishi J; Kinoshita I; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M
Anticancer Res; 2006; 26(5B):3767-72. PubMed ID: 17094399
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer.
Inoue A; Usui K; Ishimoto O; Matsubara N; Tanaka M; Kanbe M; Gomi K; Koinumaru S; Saijo Y; Nukiwa T
Lung Cancer; 2006 Apr; 52(1):83-7. PubMed ID: 16483687
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group.
Huber RM; Flentje M; Schmidt M; Pöllinger B; Gosse H; Willner J; Ulm K;
J Clin Oncol; 2006 Sep; 24(27):4397-404. PubMed ID: 16983107
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study.
Hirabayashi M; Endoh K; Teramachi M; Okuda M; Yamaguchi K; Fukuda K; Tokuhisa H; Kagioka H; Nakai N; Nakade M
Lung Cancer; 2004 Jun; 44(3):355-62. PubMed ID: 15140549
[TBL] [Abstract][Full Text] [Related]
38. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
[TBL] [Abstract][Full Text] [Related]
39. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
[TBL] [Abstract][Full Text] [Related]
40. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
